Impact of the Food and Drug Administration's Public Health Notification on the Adoption of Drug-Eluting Stents

American Journal of Cardiology

Volumn 99, Issue 9, 2007, Pages 1227-1229

  Curtis, Jeptha P ^a   Cohen, David J ^b   Jones, Philip G ^b   Bach, Richard G ^c   Spertus, John A ^b   Krumholz, Harlan M ^a  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVISORY COMMITTEE; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE UTILIZATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PRIORITY JOURNAL; PUBLIC HEALTH; SAFETY;

AGED; DISCLOSURE; FEMALE; GUIDELINE ADHERENCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; SIROLIMUS; STENTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34247489265     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.12.031     Document Type: Article

References (9)

1. Center for Devices and Radiological Health. Public health notifications. Available at: http://www.fda.gov/cdrh/safety.html. Accessed June 26, 2006.
2. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., and Kuntz R.E. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
3. Park S.J., Shim W.H., Ho D.S., Raizner A.E., Park S.W., Hong M.K., Lee C.W., Choi D., Jang Y., Lam R., Weissman N.J., and Mintz G.S. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 348 (2003) 1537-1545
4. ™ coronary stent. Available at: http://www.fda.gov/cdrh/safety/cypher.html. Accessed June 26, 2006.
5. Cordis Cypher coronary stents-possible class action. Available at: http://www.alexanderlaw.com/cordis/. Accessed January 11, 2005.
6. Spertus J.A., Peterson E., Rumsfeld J.S., Jones P.G., Decker C., and Krumholz H.M. The Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER)-evaluating the impact of myocardial infarction on patient outcomes. Am Heart J 151 (2006) 589-597
7. Muni N.I., and Gross T.P. Problems with drug-eluting coronary stents-the FDA perspective. N Engl J Med 351 (2004) 1593-1595
8. Saia F., Lemos P.A., Lee C.H., Arampatzis C.A., Hoye A., Degertekin M., Tanabe K., Sianos G., Smits P.C., McFadden E., et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: a clinical and angiographic study. Circulation 108 (2003) 1927-1929
9. ™ sirolimus-eluting coronary stent. Available at: http://www.fda.gov/cdrh/safety/cypher2.htm. Accessed November 8, 2006.